Moderate riskFDA DrugClass II

Baxter CARDENE IV nicardipine injection recalled for manufacturing quality deviations

Baxter Healthcare has recalled specific lots of CARDENE IV (nicardipine hydrochloride) injection due to deviations from manufacturing quality standards. The affected lots were distributed in the United States, Puerto Rico, and Chile.

From the FDA notice · Read the official notice ↗ · All Baxter recalls

What to do

  1. If your healthcare facility has received lots NC177818 (expires 12/31/2026) or NC188869 (expires 12/31/2027), stop using them immediately.
  2. Contact Baxter Healthcare or your supplier for return or replacement instructions.
  3. Consult your healthcare provider if you have questions about alternative treatments.

Is yours affected?

Compare your label or packaging with the recalled product.

Product
CARDENE IV (Nicardipine Hydrochloride) in 0.83% Sodium Chloride Injection, 40 mg in 200 mL (0.2 mg/mL) in GALAXY Single-Dose Container, Manufactured and Marketed by: Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 43066-016-10.
Sold in
Nationwide
Made for
Adults

This recall covers 17 products — see all of them.

Details

Units affected
N/A
Illnesses reported
None reported
Manufactured in
1 Baxter Pkwy, N/A, Deerfield, IL, United States
Classification
Class II
Recall number
D-0813-2026

In the FDA's words

Description
CARDENE IV (Nicardipine Hydrochloride) in 0.83% Sodium Chloride Injection, 40 mg in 200 mL (0.2 mg/mL) in GALAXY Single-Dose Container, Manufactured and Marketed by: Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 43066-016-10. CGMP Deviations Lot # NC177818, Exp Date: 12/31/2026; Lot # NC188869, Exp Date: 12/31/2027. Distribution: US Nationwide; Puerto Rico; and Chile. Affected quantity: N/A
Hazard
CGMP Deviations

17 products in this recall

Baxter IV drug bags recalled for manufacturing quality issues

Baxter is recalling 17 intravenous (IV) drug products for manufacturing quality problems, called CGMP deviations, which are lapses in the required production standards. The products include vancomycin, daptomycin, clindamycin, famotidine, dexmedetomidine, vasopressin, pantoprazole, insulin, nicardipine, and amiodarone, plus the brand names Myxredlin, CARDENE IV, and Nexterone. They were distributed nationwide, in Puerto Rico, and in Chile, and no injuries have been reported.

The agency lists each product separately. Check every one you might have.

More from Baxter

See all

Related topics

OtherDrugsSold nationwideMore from FDA Drug